12:00 AM
 | 
Apr 13, 2009
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 4/9 cls
Alkermes Inc. (NASDAQ:ALKS) Wedbush Patricia Bank Price target Hold -10% $8.50
Bank lowered her target to $13 from $15. Earlier this month, an FDA panel recommended approval of Victoza liraglutide, a once daily, long-acting analog of glucagon-like peptide-1 (GLP-1) from Novo Nordisk A/S (CSE:NVO; NYSE:NVO). Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) and Eli Lilly and Co. (NYSE:LLY) are developing exenatide once weekly, also a long-acting GLP-1 agonist, which uses Medisorb drug delivery technology from Alkermes. She thinks...

Read the full 577 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >